bosutinib
FDA Approves Bosulif for Pediatric Patients With CML
The FDA approved bosutinib (Bosulif, Pfizer) for pediatric patients 1 year of age and older with chronic phase (CP) ...
SEPTEMBER 28, 2023
New Indication Granted for Bosutinib to Treat Newly Diagnosed Ph+ CML
Bosulif is now indicated for adults with newly diagnosed chronic phase, Philadelphia chromosome–positive ...
DECEMBER 30, 2017
Trial Compares Bosutinib and Imatinib for First-Line CML Rx
Chicago—A Phase III head-to-head trial of bosutinib and imatinib for first-line treatment of chronic myeloid ...
SEPTEMBER 21, 2017
Load more